Genetic risk classification for adults with AML receiving less-intensive therapies: the 2024 ELN recommendations
The European LeukemiaNet (ELN) genetic risk classifications were developed based on data from younger adults receiving intensive chemotherapy. Emerging analyses from patients receiving less-intensive therapies prompted a proposal for an ELN genetic risk classification specifically for this patient population.
Authors
- Martin S. Tallman (ORCID: https://orcid.org/0000-0002-4367-6102)
- Andrew H. Wei (ORCID: https://orcid.org/0000-0002-7514-3298)
- Courtney Denton Dinardo (ORCID: https://orcid.org/0000-0001-9003-0390)
- Pierre Fenaux (ORCID: https://orcid.org/0000-0002-0468-3553)
- Agnieszka Wierzbowska (ORCID: https://orcid.org/0000-0001-7909-457X)
- Ross L. Levine (ORCID: https://orcid.org/0000-0002-7884-1905)
- Jorge Sierra (ORCID: https://orcid.org/0000-0002-7966-0356)
- Christoph Röllig (ORCID: https://orcid.org/0000-0002-3791-0548)
- Robert P. Hasserjian (ORCID: https://orcid.org/0000-0002-7753-0697)
- Dietger Niederwieser (ORCID: https://orcid.org/0000-0002-4737-1103)
- Bob Löwenberg (ORCID: https://orcid.org/0000-0001-8982-5217)
- Hervé Dombret
- Lucy A. Godley (ORCID: https://orcid.org/0000-0003-1914-9158)
- Eytan M. Stein (ORCID: https://orcid.org/0000-0001-8992-9390)
- Benjamin L. Ebert (ORCID: https://orcid.org/0000-0003-0197-5451)
- Yasushi Miyazaki (ORCID: https://orcid.org/0000-0003-3683-7147)
- Richard A. Larson (ORCID: https://orcid.org/0000-0001-9168-3203)
- Charles Craddock (ORCID: https://orcid.org/0000-0001-5041-6678)
- Jianxiang Wang (ORCID: https://orcid.org/0000-0001-9437-9151)
- Hartmut Döhner (ORCID: https://orcid.org/0000-0003-2116-5536)
- Gert Jan Ossenkoppele
- Frederick Appelbaum
- Hwei-Fang Tien
Institutions
- Northwestern University (US)
- University Hospitals Birmingham NHS Foundation Trust (GB)
- The Royal Melbourne Hospital (AU)
- Memorial Sloan Kettering Cancer Center (US)
- The University of Texas MD Anderson Cancer Center (US)
- The University of Melbourne (AU)
- Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
- University of Washington (US)
- Université Paris Cité (FR)
- Queen Elizabeth Hospital Birmingham (GB)
- Peter MacCallum Cancer Centre (AU)
- Hospital de Sant Pau (ES)
- Erasmus MC (NL)
- University of Warwick (GB)
- University of Chicago (US)
- Massachusetts General Hospital (US)
- Fred Hutch Cancer Center (US)
- Assistance Publique – Hôpitaux de Paris (FR)
- Dana-Farber Cancer Institute (US)
- Medical University of Lodz (PL)
- National Taiwan University Hospital (TW)
- Hôpital Saint-Louis (FR)
- Institute of Hematology & Blood Diseases Hospital (CN)
- Erasmus MC Cancer Institute (NL)
- Amsterdam University Medical Centers (NL)
- University Hospital Ulm (DE)
- University Hospital Carl Gustav Carus (DE)
- Nagasaki University (JP)
- Technische Universität Dresden (DE)
- Erasmus University Rotterdam (NL)
- Leipzig University (DE)
Publication Details
- Journal
- Blood
- Published
- 2024-08-12
- DOI
- https://doi.org/10.1182/blood.2024025409
- Citations
- 165
- Primary Topic
- Acute Myeloid Leukemia Research
- Type
- article
- Field-Weighted Citation Impact
- 74.97
Funders
- Amgen
- Bristol-Myers Squibb
- Pfizer
- AstraZeneca
- Gilead Sciences
- Alexion Pharmaceuticals
- Celgene
- Jazz Pharmaceuticals
- Astex Pharmaceuticals
- Foghorn Therapeutics
- Agios Pharmaceuticals
- Syndax Pharmaceuticals
- Deutsche Forschungsgemeinschaft
- Astellas Pharma
- Servier
- Genentech
- Medical Research Council
- National Health and Medical Research Council
- Daiichi Sankyo Europe